Who are the peers of the Fabino Enter?
Fabino Enter's peers include Unjha Formul., Beryl Drugs, Cian Healthcare, Adline Chem Lab, Ortin Global, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Shyama Computro. Unjha Formul. shows excellent management risk and the highest 1-year return at 23.34%, while Fabino Enter has average management risk and a 1-year return of -12.24%.
Peers: The peers of Fabino Enter are Unjha Formul., Beryl Drugs, Cian Healthcare, Adline Chem Lab, Ortin Global, Vivanza Biosci., Ganga Pharma., Brawn Biotech, Shyama Computro.Quality Snapshot: Excellent management risk is observed at Unjha Formul., while Average management risk is found at Fabino Enter and the rest. Below Average management risk is noted for Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Brawn Biotech. Adline Chem Lab and Shyama Computro. do not qualify for management risk assessment. Growth is Below Average for Fabino Enter, Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Brawn Biotech, while Adline Chem Lab and Shyama Computro. do not qualify. Capital Structure is Good at Unjha Formul., Average at Fabino Enter, and Below Average for Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Brawn Biotech, with Adline Chem Lab and Shyama Computro. not qualifying.
Return Snapshot: Unjha Formul. has the highest 1-year return at 23.34%, while Cian Healthcare has the lowest at -81.16%. Fabino Enter's 1-year return is -12.24%, which is better than Cian Healthcare but worse than Unjha Formul. Additionally, Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Brawn Biotech all have negative six-month returns.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
